ACROBiosystems AD
 
 

BRIC

검색 닫기

전체 메뉴

팝업 닫기

바이오젬스코리아

  • 등록2026.07.09
  • 조회11
Anti-Human CD28 SAFIRE Purified ( CD28.2 ) [ 10311-25 ] : SAFIRE AB

Anti-Human CD28 SAFIRE Purified ( CD28.2 ) [ 10311-25 ] : SAFIRE AB

본 정보는 "바이오젬스코리아"(으)로 문의 바랍니다.

제품문의 메일보내기바이오젬스코리아 홈페이지 가기BioGems 홈페이지 가기


Anti-Human CD28 SAFIRE Purified ( Clone : CD28.2 )  

SAFIRE(Sodium Azide Free Immensely Reduced Endotoxin) 제품은 면역세포 activation, blocking, neutralization 연구에 사용할 수 있는 BioGems의 기능성 항체 라인입니다. 이 제품은 career 및 sodium azide 를  전혀 포함하지 않으며,  in vivo 및 in vitro 사용가능한 0.01 EU/ug 이하의 내독소 수준으로 제조된 제품입니다.

CD28.2 단일클론 항체는 대부분의 성숙 T 림프구, 혈장 세포 및 흉선 세포의 표면에서 발현되는 인간 44 kDa 동종이량체 막횡단 당단백질 CD28에 대하여 특이적으로 결합합니다.

CD28은 T 림프구의 공동 자극자인 B7-1(CD80)과 B7-2(CD86)에 대한 리간드로써,  T 림프구와 B 림프구 사이의 상호 작용을 향상 시킵니다.

IL-2를 생성하기 위한 T 림프구 자극은 관련된 단클론 항체에 달려 있다고 보고되었으며, 이는 CD28 분자가 뚜렷한 기능을 가진 일부 하위 영역을 제공한다는 것을 암시합니다.

CD28.2 항체는 Jurkat T 림프구에서 Ca2 유입을 유도합니다. 다른 연구에서는 CD28이 신호 전달에 관여하는 것으로 나타났습니다.

Catalog Number : 10311-25  ;  Clone:   CD28.2 
SIZE가격 (부가세별도)제품번호
100 μg
$130.00 
10311-25-100
500 μg
$260.00 
10311-25-500


ADDITIONAL CD28.2 FORMATS  

CAT.NO.FORMATSTARTING FROM
10311-77PE-Cyanine7$ 115.00
10311-20Purified$ 75.00
10311-25SAFIRE Purified$ 130.00
10311-50FITC$ 70.00
10311-80APC$ 105.00
10311-60PE$ 80.00
10311-70PerCP-Cyanine5.5$ 135.00

 

[ 최신 제품 인용 논문]   

  1. Su Z, Chen Z, Lin J, Yu W, Zeng Y, Zhang W, Li Q, Lin Y, Liu Z, Zheng G, Li L, Xie Z. Neutrophil membrane-coated and MMP2-responsive nanoparticles deliver PIM1 inhibitor to alleviate inflammatory arthritis through inhibiting Th17 cell differentiation. J Nanobiotechnology. 2026 Mar 14;24(1):379. doi: 10.1186/s12951-026-04280-x. PMID: 41827025; PMCID: PMC13101309.
  2. Cheng C, Su H, Li X, Li R, Yang Q, Guan T, Li M, Ou C. MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation. J Nanobiotechnology. 2026 Mar 2;24(1):203. doi: 10.1186/s12951-026-04212-9. PMID: 41772611; PMCID: PMC12955233.
  3. Zhang XY, Shi JB, Jin SF, Wang RJ, Li MY, Zhang ZY, Yang X, Ma HL. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. Cancer Commun (Lond). 2024 Jun;44(6):670-694. doi: 10.1002/cac2.12545. Epub 2024 May 12. PMID: 38734931; PMCID: PMC11194450.
  4. Li XY, Xie XQ, Wei BC, Sun XZ, Chen MX, Liu RF, Tao QX, Huang YH, Wang Q, Ma SS, Wei L, Xiao R, Liu ZY, Yu JM, Wu M, Chen D. IL-21 enhances the cytotoxicity of intratumoral CD8+ T cells, improving radiation efficacy. JCI Insight. 2026 Jan 8;11(4):e190531. doi: 10.1172/jci.insight.190531. PMID: 41505202; PMCID: PMC12956009.
  5. Yu W, Wang K, He Y, Shang Y, Hu X, Deng X, Zhao L, Ma X, Mu X, Li R, Gao Z. The potential role of lung microbiota and lauroylcarnitine in T-cell activation associated with checkpoint inhibitor pneumonitis. EBioMedicine. 2024 Aug 3:106:105267. doi: 10.1016/j.ebiom.2024.105267. Epub ahead of print. PMID: 39098109.
  6. Zhang X, Chen R, Huo Z, Li W, Jiang M, Su G, Liu Y, Cai Y, Huang W, Xiong Y, Wang S. Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer. Cancer Cell Int. 2024 Jun 29;24(1):225. doi: 10.1186/s12935-024-03412-3. PMID: 38951894; PMCID: PMC11218110.
  7. Liu L, Xiang Y, Shao L, Yuan C, Song X, Sun M, Liu Y, Zhang X, Du S, Hou M, Peng J, Shi Y. E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia. J Thromb Haemost. 2024 Apr;22(4):1202-1214. doi: 10.1016/j.jtha.2023.12.032. Epub 2024 Jan 4. PMID: 38184203.
  8. Lin Q, Wu F, Zhang L, Zhang Y, Sun S, Wu X, Yu H. EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation. Acta Biochim Biophys Sin (Shanghai). 2026 Mar 3. doi: 10.3724/abbs.2026013. Epub ahead of print. PMID: 41772962.
  9. Qian Y, Sun Y, Shi P, Zhou X, Zhang Q, Dong Q, Jin S, Qiu L, Niu X, Zhou X, Zhao W, Wu Y, Zhai W, Gao Y. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. Acta Pharm Sin B. 2024 Mar;14(3):1150-1165. doi: 10.1016/j.apsb.2023.12.011. Epub 2023 Dec 19. PMID: 38486998; PMCID: PMC10935467.
  10. Su Z, Li J, Lin J, Li Z, Che Y, Zhang Z, Zheng G, Ye G, Yu W, Zeng Y, Xu P, Xu X, Xie Z, Wu Y, Shen H. TNF-α-Induced KAT2A Impedes BMMSC Quiescence by Mediating Succinylation of the Mitophagy-Related Protein VCP. Adv Sci (Weinh). 2024 Mar;11(10):e2303388. doi: 10.1002/advs.202303388. Epub 2023 Dec 25. PMID: 38145956; PMCID: PMC10933659.  [ BioGems 제품이나 Peprotech 으로 표기 ]
  11. Jin S, Wang H, Li Y, Yang J, Li B, Shi P, Zhang X, Zhou X, Zhou X, Niu X, Wu M, Wu Y, Zhai W, Qi Y, Gao Y, Zhao W. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy. Cell Commun Signal. 2024 Mar 11;22(1):173. doi: 10.1186/s12964-024-01555-4. PMID: 38462636; PMCID: PMC10926604.
  12. Han K, Li SS, Pan W, Xu MN, Zhong MZ, Zhang WJ, Huang XW, Zeng K. ERK/MEK Pathway Regulates Th17 Cell Differentiation in Patients with Pemphigus Vulgaris. Indian J Dermatol. 2023 Nov-Dec;68(6):724. doi: 10.4103/ijd.ijd_924_22. Epub 2024 Jan 9. PMID: 38371571; PMCID: PMC10868988.
  13. Han K, Li SS, Pan W, Xu MN, Zhong MZ, Zhang WJ, Huang XW, Zeng K. ERK/MEK Pathway Regulates Th17 Cell Differentiation in Patients with Pemphigus Vulgaris. Indian J Dermatol. 2023 Nov-Dec;68(6):724. doi: 10.4103/ijd.ijd_924_22. Epub 2024 Jan 9. PMID: 38371571; PMCID: PMC10868988.
  14. Yuzhen Qian, Yixuan Sun, Peishang Shi, Xiuman Zhou, Qiongqiong Zhang, Qingyu Dong, Shengzhe Jin, Lu Qiu, Xiaoshuang Niu, Xiaowen Zhou, Wenshan Zhao, Yahong Wu, Wenjie Zhai, Yanfeng Gao, Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy, Acta Pharmaceutica Sinica B,2023. https://doi.org/10.1016/j.apsb.2023.12.011.
  15. Han SM, Park ES, Park J, Nahmgoong H, Choi YH, Oh J, Yim KM, Lee WT, Lee YK, Jeon YG, Shin KC, Huh JY, Choi SH, Park J, Kim JK, Kim JB. Unique adipose tissue invariant natural killer T cell subpopulations control adipocyte turnover in mice. Nat Commun. 2023 Dec 21;14(1):8512. doi: 10.1038/s41467-023-44181-3. PMID: 38129377; PMCID: PMC10739728.
  16. Li P, Zhou D, Chen D, Cheng Y, Chen Y, Lin Z, Zhang X, Huang Z, Cai J, Huang W, Lin Y, Ke H, Long J, Zou Y, Ye S, Lan P. Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer. J Biomed Sci. 2023 Jun 28;30(1):47. doi: 10.1186/s12929-023-00930-6. PMID: 37380972; PMCID: PMC10303345.
  17. Nahmad AD, Reuveni E, Goldschmidt E, Tenne T, Liberman M, Horovitz-Fried M, Khosravi R, Kobo H, Reinstein E, Madi A, Ben-David U, Barzel A. Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat Biotechnol. 2022 Dec;40(12):1807-1813. doi: 10.1038/s41587-022-01377-0. Epub 2022 Jun 30. PMID: 35773341; PMCID: PMC7613940.
  18. Chen J, Shen Z, Jiang X, Huang Z, Wu C, Jiang D, Yin L. Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex. Antib Ther. 2022 Nov 17;6(1):38-48. doi: 10.1093/abt/tbac031. PMID: 36683766; PMCID: PMC9847340.
  19. Li J, Jin J, Li S, Zhong Y, Jin Y, Zhang X, Xia B, Zhu Y, Guo R, Sun X, Guo J, Hu F, Xiao W, Huang F, Ye H, Li R, Zhou Y, Xiang X, Yao H, Yan Q, Su L, Wu L, Luo T, Liu Y, Guo X, Qin J, Qi H, He J, Wang J, Li Z. Tonsillar Microbiome-Derived Lantibiotics Induce Structural Changes of IL-6 and IL-21 Receptors and Modulate Host Immunity. Adv Sci (Weinh). 2022 Oct;9(30):e2202706. doi: 10.1002/advs.202202706. Epub 2022 Aug 28. PMID: 36031409; PMCID: PMC9596850.
  20. Zhan Y, Cao J, Ji L, Zhang M, Shen Q, Xu P, Zhuang X, Qin S, Hua F, Sun L, Li F, Chen H, Cheng Y. Impaired mitochondria of Tregs decreases OXPHOS-derived ATP in primary immune thrombocytopenia with positive plasma pathogens detected by metagenomic sequencing. Exp Hematol Oncol. 2022 Sep 1;11(1):48. doi: 10.1186/s40164-022-00304-y. PMID: 36050760; PMCID: PMC9434515.

 

ADDITIONAL INFORMATION

Clone:
CD28.2
Format:
SAFIRE Purified
Applications:
FC, FA, IHC, IP
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest:Adaptive Immunity
Cell Type:T Cells
Application:FC, FA, IHC, IP
Clone:CD28.2
Preparation:
The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/µg of the protein.
Formulation:
Phosphate-buffered aqueous solution, ph7.2.
References:

Schlossman, S., L. Bloumsell, et al. eds (1995). Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press. New York

Nunès, J., Klasen, S., Ragueneau, M., Pavon, C., Couez, D., Mawas, C., … & Olive, D. (1993). CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events.International immunology, 5(3), 311-315.

Karlsson, I., Malleret, B., Brochard, P., Delache, B., Calvo, J., Le Grand, R., & Vaslin, B. (2007). FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. Journal of virology, 81(24), 13444-13455.

제품문의 메일보내기바이오젬스코리아 홈페이지 가기BioGems 홈페이지 가기
BioGems SAFIRE 항체 : Anti-Human CD28 SAFIRE Purified ( CD28.2 ) [ 10311-25 ] Anti-Human CD28 SAFIRE Purified ( CD28.2 ) [ 10311-25 ] : BioGems SAFIRE AB

본 정보는 "바이오젬스코리아"(으)로 문의 바랍니다.

목록

연구용제품 > 바이오젬스코리아

기업정보 바로가기 >

필코리아테크놀로지 AD